drugset / Trial / NCT06636500

A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects

NCT06636500 ↗

Phase 1 Completed 72 enrolled Cullgen Australia Pty Ltd
RandomizedParallel-groupQuadruple-blindOther

Summary

This is a dose finding study of CG001419, administered as a single dose, with or without food, and as multiple doses. CG001419 is being tested in healthy volunteers in this trial with the goal of eventually developing the drug for patients with pain if it is found to be safe and well tolerated.

Timeline

Start
2025-01-22
Primary completion
2025-12-05
Completion
2025-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CG001419 Unknown — Oral

Indications

No indication recorded.